Polycystic ovary syndrome, recently proposed to be renamed polyendocrine metabolic ovarian syndrome (PMOS), is a reproductive endocrine-metabolic disorder affecting women of reproductive age. It is clinically defined by hyperandrogenemia, ovulatory dysfunction, and polycystic ovarian morphology, often accompanied by metabolic abnormalities like insulin resistance and obesity. The pathogenesis of PCOS remains complex and incompletely understood. Research indicates that epigenetic modifications are involved in the initiation and progression of the disorder. These modifications, including DNA methylation, histone modifications, and non-coding RNA regulation, alter gene expression without changing the DNA sequence. This contributes to conditions such as ovarian dysfunction, hormonal imbalance, and metabolic dysregulation. Aberrant DNA methylation affects genes involved in steroid hormone synthesis and metabolic regulation, contributing to hyperandrogenemia and insulin resistance. Histone modifications, including acetylation and methylation, alter chromatin structure and regulate genes essential for follicular development, leading to ovulatory disorders. Non-coding RNAs, such as microRNAs and long non-coding RNAs, further exacerbate the PCOS phenotype by targeting genes involved in hormone biosynthesis and insulin signaling pathways. Environmental factors, including the intrauterine environment and exposure to endocrine-disrupting chemicals, can induce abnormal epigenetic modifications and interact with genetic susceptibility, increasing the risk of PCOS. A comprehensive understanding of these mechanisms provides insights into the disorder’s etiology and a foundation for developing diagnostic biomarkers and therapeutic strategies based on epigenetic regulation.